Previous 10 | Next 10 |
Boston (March 25, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that the Company has been granted a formal exten...
2024-03-08 08:44:33 ET More on Allarity Therapeutics Allarity Therapeutics appoints co-founder Thomas Jensen as interim CEO Seeking Alpha’s Quant Rating on Allarity Therapeutics Historical earnings data for Allarity Therapeutics Financial information f...
Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graff, Ph.D., former Eli Lilly Executive, as Executive Advisor Reduced Net Loss from Operations by 50% and Reduced Net Loss by 26% Announced Data in December 2023 from Advanced Ovar...
Genesco Inc. (GCO) is expected to report $2.66 for Q4 2024 Broadway Financial Corporation (BYFC) is expected to report for quarter end 2023-12-31 Oji Holdings Corporation ADR (OJIPY) is expected to report for Q3 2024 Hibbett Inc. (HIBB) is expected to report $2.54 for Q4 2024 GRI ...
Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at...
2024-01-08 14:54:36 ET More on Markets Cathie Wood: Probability is very high that a Spot Bitcoin ETF will be approved this week Market returns are broadening out from the Magnificent 7 - Principal Financial Group Real Estate is the top performing sector since the mar...
2023-12-12 06:09:27 ET More on Allarity Therapeutics Allarity stock soars 60% premarket on ovarian cancer therapy results Seeking Alpha’s Quant Rating on Allarity Therapeutics Historical earnings data for Allarity Therapeutics Financial information for...
Boston (December 12, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized c...
2023-12-06 07:22:53 ET DENVER, Colo., Dec. 6, 2023 ( www.247marketnews.com )- The following companies published announcements or traded higher on higher-than-usual volume; Siyata Mobile (NASDAQ: SYTA), Incannex Healthcare Inc (NASDAQ: IXHL), Yoshiharu Global Co. (NASDAQ: YOSH), Allarity...
2023-12-05 09:55:33 ET DENVER, Colo., Dec. 5, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Allarity Therapeutics Inc (NASDAQ: ALLR), Clearmind Medicine Inc (NASDAQ: CMND), Harbor Custom Development Inc...
News, Short Squeeze, Breakout and More Instantly...
Allarity Therapeutics Inc. Company Name:
ALLR Stock Symbol:
NASDAQ Market:
Allarity Therapeutics Inc. Website:
Boston (June 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it received notice from the NASDAQ S...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 6.8% to $126.09 on volume of 414,790,976 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 18.7% to $0.265 on volume of 162,165,405 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 12.6%...
Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer...